Riverbridge Partners LLC lowered its position in Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 75.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,228 shares of the company's stock after selling 28,598 shares during the quarter. Riverbridge Partners LLC's holdings in Roche were worth $376,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in RHHBY. Fulton Bank N.A. raised its stake in Roche by 2.6% during the first quarter. Fulton Bank N.A. now owns 12,620 shares of the company's stock worth $518,000 after acquiring an additional 314 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Roche by 2.0% in the first quarter. PNC Financial Services Group Inc. now owns 16,234 shares of the company's stock valued at $668,000 after buying an additional 323 shares during the period. Confluence Investment Management LLC boosted its position in shares of Roche by 3.6% in the 1st quarter. Confluence Investment Management LLC now owns 14,491 shares of the company's stock worth $596,000 after purchasing an additional 510 shares during the last quarter. Accent Capital Management LLC acquired a new position in shares of Roche during the 1st quarter worth about $35,000. Finally, North Star Asset Management Inc. increased its stake in Roche by 7.8% in the first quarter. North Star Asset Management Inc. now owns 17,305 shares of the company's stock valued at $712,000 after purchasing an additional 1,255 shares in the last quarter.
Roche Price Performance
Shares of RHHBY opened at $39.96 on Friday. The stock has a 50 day simple moving average of $40.51 and a 200 day simple moving average of $40.30. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 0.85. Roche Holding AG has a 52-week low of $34.10 and a 52-week high of $44.31.
Roche Company Profile
(
Free Report)
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
Further Reading
Want to see what other hedge funds are holding RHHBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holding AG (OTCMKTS:RHHBY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Roche, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.
While Roche currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.